

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

Name of entity

Nagambie Resources Limited

ABN

42 111 587 163

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- | | | |
|---|---|---|
| 1 | +Class of +securities issued or to be issued | Convertible notes. |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued | 18,000,000 |
| 3 | Principal terms of the +securities (e.g. if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion) | Duration: 5 year term ending 17 November 2022.
Conversion: Notes are convertible at any time within the 5-year term into Nagambie Resources fully paid ordinary shares on a 1 for 1 basis.
Redemption: Notes are redeemable at \$0.10 per note after 5 years if not previously converted. |

+ See chapter 19 for defined terms.

For personal use only

4	<p>Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?</p> <p>If the additional +securities do not rank equally, please state:</p> <ul style="list-style-type: none"> • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	<p>On conversion, the convertible notes will rank equally with Nagambie Resources fully paid ordinary shares on issue. Notes accrue interest at 10% per annum, payable every 6 months within the term of the Notes, ending on 17 November 2022.</p>
5	<p>Issue price or consideration</p>	<p>\$0.10 per Share.</p>
6	<p>Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)</p>	<p>The purpose of this issue is to increase the working capital of the Company.</p>
6a	<p>Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?</p>	<p>Yes.</p>
	<p>If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i</p>	
6b	<p>The date the security holder resolution under rule 7.1A was passed</p>	<p>25 November 2016.</p>
6c	<p>Number of +securities issued without security holder approval under rule 7.1</p>	<p>18,000,000 convertible notes.</p>
6d	<p>Number of +securities issued with security holder approval under rule 7.1A</p>	<p>Nil.</p>

6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	Nil.					
6f	Number of +securities issued under an exception in rule 7.2	Nil.					
6g	If +securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the +issue date and both values. Include the source of the VWAP calculation.	N/A.					
6h	If +securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A.					
6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	7.1 Capacity: 35,368,720 7.1A Capacity: 40,156,925					
7	<p>+Issue dates</p> <p>Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.</p> <p>Cross reference: item 33 of Appendix 3B.</p>	17 November 2017.					
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	<table border="1"> <thead> <tr> <th data-bbox="783 1592 1082 1603">Number</th> <th data-bbox="1082 1592 1377 1603">+Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="783 1603 1082 1827">403,935,912</td> <td data-bbox="1082 1603 1377 1827">Ordinary Shares</td> </tr> </tbody> </table>	Number	+Class	403,935,912	Ordinary Shares	
Number	+Class						
403,935,912	Ordinary Shares						

+ See chapter 19 for defined terms.

<p>9 Number and ⁺class of all ⁺securities not quoted on ASX (including the ⁺securities in section 2 if applicable)</p>	<table border="1"> <thead> <tr> <th data-bbox="710 324 1013 369">Number</th> <th data-bbox="1013 324 1316 369">⁺Class</th> </tr> </thead> <tbody> <tr> <td data-bbox="710 369 1013 481">4,750,000</td> <td data-bbox="1013 369 1316 481">Options exercisable at \$0.10 vesting 31 October 2012 and expiring 31 October 2017.</td> </tr> <tr> <td data-bbox="710 481 1013 593">9,500,000</td> <td data-bbox="1013 481 1316 593">Options exercisable at \$0.10 vesting 3 December 2013 and expiring on 3 December 2018.</td> </tr> <tr> <td data-bbox="710 593 1013 705">10,500,000</td> <td data-bbox="1013 593 1316 705">Options exercisable at \$0.10 vesting 28 December 2014 and expiring on 28 November 2019.</td> </tr> <tr> <td data-bbox="710 705 1013 817">3,500,000</td> <td data-bbox="1013 705 1316 817">Options exercisable at \$0.10 vesting 29 October 2015 and expiring on 16 November 2020.</td> </tr> <tr> <td data-bbox="710 817 1013 929">8,000,000</td> <td data-bbox="1013 817 1316 929">Options exercisable at \$0.10 vesting 16 November 2015 and expiring on 16 November 2020.</td> </tr> <tr> <td data-bbox="710 929 1013 1041">2,000,000</td> <td data-bbox="1013 929 1316 1041">Options exercisable at \$0.255 vesting 4 July 2016 and expiring on 4 July 2021.</td> </tr> <tr> <td data-bbox="710 1041 1013 1153">12,500,000</td> <td data-bbox="1013 1041 1316 1153">Options exercisable at \$0.25 vesting 30 November 2016 and expiring on 30 November 2021.</td> </tr> <tr> <td data-bbox="710 1153 1013 1265">18,680,000</td> <td data-bbox="1013 1153 1316 1265">Convertible notes each convertible into 1 ordinary share on or before 15 April 2020.</td> </tr> <tr> <td data-bbox="710 1265 1013 1377">3,333,333</td> <td data-bbox="1013 1265 1316 1377">Convertible notes each convertible into 1 ordinary share on or before 17 September 2021.</td> </tr> <tr> <td data-bbox="710 1377 1013 1489">18,000,000</td> <td data-bbox="1013 1377 1316 1489">Convertible notes each convertible into 1 ordinary share on or before 17 November 2022.</td> </tr> </tbody> </table>	Number	⁺ Class	4,750,000	Options exercisable at \$0.10 vesting 31 October 2012 and expiring 31 October 2017.	9,500,000	Options exercisable at \$0.10 vesting 3 December 2013 and expiring on 3 December 2018.	10,500,000	Options exercisable at \$0.10 vesting 28 December 2014 and expiring on 28 November 2019.	3,500,000	Options exercisable at \$0.10 vesting 29 October 2015 and expiring on 16 November 2020.	8,000,000	Options exercisable at \$0.10 vesting 16 November 2015 and expiring on 16 November 2020.	2,000,000	Options exercisable at \$0.255 vesting 4 July 2016 and expiring on 4 July 2021.	12,500,000	Options exercisable at \$0.25 vesting 30 November 2016 and expiring on 30 November 2021.	18,680,000	Convertible notes each convertible into 1 ordinary share on or before 15 April 2020.	3,333,333	Convertible notes each convertible into 1 ordinary share on or before 17 September 2021.	18,000,000	Convertible notes each convertible into 1 ordinary share on or before 17 November 2022.	<p>10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)</p>
Number	⁺ Class																							
4,750,000	Options exercisable at \$0.10 vesting 31 October 2012 and expiring 31 October 2017.																							
9,500,000	Options exercisable at \$0.10 vesting 3 December 2013 and expiring on 3 December 2018.																							
10,500,000	Options exercisable at \$0.10 vesting 28 December 2014 and expiring on 28 November 2019.																							
3,500,000	Options exercisable at \$0.10 vesting 29 October 2015 and expiring on 16 November 2020.																							
8,000,000	Options exercisable at \$0.10 vesting 16 November 2015 and expiring on 16 November 2020.																							
2,000,000	Options exercisable at \$0.255 vesting 4 July 2016 and expiring on 4 July 2021.																							
12,500,000	Options exercisable at \$0.25 vesting 30 November 2016 and expiring on 30 November 2021.																							
18,680,000	Convertible notes each convertible into 1 ordinary share on or before 15 April 2020.																							
3,333,333	Convertible notes each convertible into 1 ordinary share on or before 17 September 2021.																							
18,000,000	Convertible notes each convertible into 1 ordinary share on or before 17 November 2022.																							

10% per annum interest rate payable every 6 months.

Part 2 - Pro rata issue

11	Is security holder approval required?	N/A.
12	Is the issue renounceable or non-renounceable?	N/A.
13	Ratio in which the +securities will be offered	N/A.
14	+Class of +securities to which the offer relates	N/A.
15	+Record date to determine entitlements	N/A.
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A.
17	Policy for deciding entitlements in relation to fractions	N/A.
18	Names of countries in which the entity has security holders who will not be sent new offer documents <small>Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.</small>	N/A.
19	Closing date for receipt of acceptances or renunciations	N/A.

+ See chapter 19 for defined terms.

20	Names of any underwriters	N/A.
21	Amount of any underwriting fee or commission	N/A.
22	Names of any brokers to the issue	N/A.
23	Fee or commission payable to the broker to the issue	N/A.
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A.
25	If the issue is contingent on security holders' approval, the date of the meeting	N/A.
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A.
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A.
28	Date rights trading will begin (if applicable)	N/A.
29	Date rights trading will end (if applicable)	N/A.
30	How do security holders sell their entitlements <i>in full</i> through a broker?	N/A.
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A.

+ See chapter 19 for defined terms.

32 How do security holders dispose of their entitlements (except by sale through a broker)?

33 ⁺Issue date

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34 Type of ⁺securities
(tick one)

(a) ⁺Securities described in Part 1

(b) All other ⁺securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35 If the ⁺securities are ⁺equity securities, the names of the 20 largest holders of the additional ⁺securities, and the number and percentage of additional ⁺securities held by those holders

36 If the ⁺securities are ⁺equity securities, a distribution schedule of the additional ⁺securities setting out the number of holders in the categories

1 - 1,000

1,001 - 5,000

5,001 - 10,000

10,001 - 100,000

100,001 and over

37 A copy of any trust deed for the additional ⁺securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38 Number of +securities for which +quotation is sought

--

39 +Class of +securities for which quotation is sought

--

40 Do the +securities rank equally in all respects from the +issue date with an existing +class of quoted +securities?

If the additional +securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

--

41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period

(if issued upon conversion of another +security, clearly identify that other +security)

--

42	Number and +class of all +securities quoted on ASX (including the +securities in clause 38)	Number	+Class

+ See chapter 19 for defined terms.

For personal use only

Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.

- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.


Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:



(Company secretary)

Date: 20 November 2017

Print name: Alfonso Grillo

+ See chapter 19 for defined terms.

For personal use only

Appendix 3B – Annexure 1

Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

Part 1

Rule 7.1 – Issues exceeding 15% of capital	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	367,879,776
<p>Add the following:</p> <ul style="list-style-type: none"> • Number of fully paid +ordinary securities issued in that 12 month period under an exception in rule 7.2 • Number of fully paid +ordinary securities issued in that 12 month period with shareholder approval • Number of partly paid +ordinary securities that became fully paid in that 12 month period <p><i>Note:</i></p> <ul style="list-style-type: none"> • <i>Include only ordinary securities here – other classes of equity securities cannot be added</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>21,289,447 fully paid ordinary shares (Issued 4 May 2017, Rule 7.2, Exception 4).</p> <p>12,000,022 fully paid ordinary shares (Issued 15 March 2017, Rule 7.2, Exception 15).</p> <p>400,000 fully paid ordinary shares (Issued 29 November 2016, Rule 7.2, Exception 4).</p>
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil
“A”	401,569,245

+ See chapter 19 for defined terms.

For personal use only

Step 2: Calculate 15% of “A”	
“B”	0.15 <i>[Note: this value cannot be changed]</i>
Multiply “A” by 0.15	60,235,387
Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used	
<p>Insert number of +equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> • Under an exception in rule 7.2 • Under rule 7.1A • With security holder approval under rule 7.1 or rule 7.4 <p>Note:</p> <ul style="list-style-type: none"> • <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i> • <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	<p>4,500,000 options (30 November 2016)</p> <p>2,366,667 fully paid ordinary shares (Issued 15 March 2017).</p> <p>18,000,000 convertible notes (17 November 2017)</p>
“C”	24,866,667
Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	60,235,387
<p>Subtract “C”</p> <p><i>Note: number must be same as shown in Step 3</i></p>	24,866,667
Total [“A” x 0.15] – “C”	35,368,720 <i>[Note: this is the remaining placement capacity under rule 7.1]</i>

+ See chapter 19 for defined terms.

Part 2

Rule 7.1A – Additional placement capacity for eligible entities	
Step 1: Calculate “A”, the base figure from which the placement capacity is calculated	
“A” <i>Note: number must be same as shown in Step 1 of Part 1</i>	401,569,245
Step 2: Calculate 10% of “A”	
“D”	0.10 <i>Note: this value cannot be changed</i>
Multiply “A” by 0.10	40,156,925
Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used	
Insert number of +equity securities issued or agreed to be issued in that 12 month period under rule 7.1A <i>Notes:</i> <ul style="list-style-type: none"> • <i>This applies to equity securities – not just ordinary securities</i> • <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i> • <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i> • <i>It may be useful to set out issues of securities on different dates as separate line items</i> 	
“E”	0

+ See chapter 19 for defined terms.

For personal use only

Step 4: Subtract “E” from [“A” x “D”] to calculate remaining placement capacity under rule 7.1A	
“A” x 0.10 <i>Note: number must be same as shown in Step 2</i>	40,156,925
Subtract “E” <i>Note: number must be same as shown in Step 3</i>	0
Total [“A” x 0.10] – “E”	40,156,925 <i>Note: this is the remaining placement capacity under rule 7.1A</i>

+ See chapter 19 for defined terms.